COVID-19

T cells will save us from COVID-19, part two

T cells are the other arm of the adaptive immune response (in addition to B cells) that are essential for clearing virus infections. Most studies of immunity to SARS-CoV-2 infection have focused on antibodies and their ability to neutralize virus infection. The observation that variants of concern are less effectively neutralized by antibodies against ancestral …

T cells will save us from COVID-19, part two Read More »

SARS-CoV-2 variants arise during individual infections

Early in the COVID-19 pandemic, SARS-CoV-2 genome variation appeared to be low, with an average of 10 base differences in the 30,000 base genome between any two isolates. Late in 2020, as many more people were infected, variants were isolated that had more changes than previously seen. A study of variation at the genome level …

SARS-CoV-2 variants arise during individual infections Read More »

SARS-CoV-2 variant B.1.1.7 is not more virulent

When the B.1.1.7 variant of SARS-CoV-2 was first detected in the UK in December 2020 it was accompanied by unsubstantiated claims of increased transmissibility and virulence. The results of a hospital-based study in London reveals no association of the variant with severe disease in this cohort. In a note published by NERVTAG on 21 January …

SARS-CoV-2 variant B.1.1.7 is not more virulent Read More »

A tapeworm drug to treat COVID-19?

Niclosamide (pictured) is a drug that has been approved in humans to treat infections with a variety of tapeworms. It might be useful for preventing SARS-CoV-2 replication and COVID-19 pathogenesis by inhibiting virus-catalyzed membrane fusion. Examination of the lungs of 41 patients who died of COVID-19 revealed, in addition to expected lung injury, the presence …

A tapeworm drug to treat COVID-19? Read More »

Scroll to Top